The Pediatric infectious disease journalFemaleHumansInfantMaleAlaska
Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024.
Laura L Hammitt, Joel S Espinoza, James W Keck, Rachel M Hartman, Gilberto Alvarez-Colon, Amanda Burrage, Angela P Campbell, Fernando Cardona, James Chappell, Loretta Christensen, Fatimah S Dawood, Christine Desnoyers, Jennifer Dobson, Natasha Halasa, Chloe Hurley
Published: 202510.1097/INF.0000000000004942
Abstract
Open AccessNirsevimab is recommended to prevent severe respiratory syncytial virus (RSV)-associated illness among American Indian/Alaska Native (AI/AN) children <20 months of age. In a test-negative case-control analysis among 291 AI/AN children hospitalized during the 2023-2024 season, nirsevimab was 86.0% and 87.9% effective among children entering their first and second RSV seasons, respectively.